“Just because your doctor has a name for your condition doesn’t mean he knows what it is.” Bertrand Russell
For many years, numerous risk scores, for example, International Prognostic Index for non-Hodgkin lymphoma (NHL) or Revised International Prognostic Scoring System for myelodysplastic syndrome (MDS) were introduced to predict outcome. The subtle prediction of outcome was contrasted by only a small number of therapeutic options and Cyclophosphamide, Hydroxydaunorubicin, Oncovin and Prednisone (CHOP) chemotherapy or supportive therapy was standard of care in the aforementioned entities. More recently positron emission tomography (PET) was preferred to identify early NHL responders who were likely to have a long-term survival. As a consequence, current trials used escalated therapy for the poor risk group but failed to improve poor outcome of PET-positive NHL as described by M. Fridrik [ 1 ].